Stryker Corporation $SYK Shares Bought by State Street Corp

Posted by Stanley Muller on Sep 22nd, 2026

State Street Corp lifted its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 1.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,532,565 shares of the medical technology company’s stock after purchasing an additional 183,400 shares during the period. State Street Corp owned about 4.05% of Stryker worth $4,903,772,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Amundi raised its holdings in Stryker by 18.3% during the second quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock worth $392,402,000 after purchasing an additional 192,447 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Stryker by 8.2% during the second quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock valued at $270,642,000 after purchasing an additional 65,333 shares during the last quarter. Veritas Asset Management LLP acquired a new position in shares of Stryker in the second quarter worth about $168,057,000. Rakuten Investment Management Inc. acquired a new position in Stryker in the 2nd quarter worth approximately $18,646,000. Finally, Bank of America Corp DE purchased a new position in shares of Stryker during the second quarter valued at $1,404,284,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock traded up $2.52 during midday trading on Tuesday, reaching $276.71. The company had a trading volume of 635,307 shares, compared to its average volume of 2,434,301. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $106.14 billion, a price-to-earnings ratio of 28.70, a price-to-earnings-growth ratio of 1.74 and a beta of 0.76. The stock has a fifty day simple moving average of $318.75 and a 200 day simple moving average of $321.61. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $392.55.

Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 15 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.3%. Stryker’s dividend payout ratio is presently 36.48%.

Analyst Ratings Changes

SYK has been the topic of several research analyst reports. Truist Financial boosted their price target on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. Raymond James Financial set a $370.00 price target on shares of Stryker in a research report on Friday, July 31st. Piper Sandler cut their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Wells Fargo & Company cut their target price on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $317.00 price objective on shares of Stryker in a research report on Wednesday, September 9th. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $374.42.

Read Our Latest Research Report on SYK

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by insiders.

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.